ATAI Stock Analysis: ATAI Life Sciences BV | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.911m USD | 12M Return: 88.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.9M
Qual. Beats: 0
Rev. Trend: 89.5%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders, operating in the United States, Germany, and Canada. As a pre-revenue biotechnology firm, the companys value is tied to its R&D pipeline rather than commercial product sales, placing it in the speculative segment of the health care sector where investors typically evaluate candidates by clinical stage, mechanism of action, and addressable indications rather than current earnings.
The companys pipeline spans several psychiatric indications and includes BPL-003, an intranasal mebufotenin formulation in Phase 2a/2b studies for treatment-resistant depression (TRD) and alcohol use disorder; RL-007, a pro-cognitive neuromodulator in Phase 2b for cognitive impairment associated with schizophrenia; ELE-101, a serotonergic psychedelic for major depressive disorder; VLS-01, an oral transmucosal DMT film in Phase 2 for TRD; EMP-01, an oral R-MDMA formulation in Phase 2 for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists targeting TRD. Additional programs include COMP360 psilocybin therapy and GRX-917 for anxiety, depression, and neurological disorders, reflecting a strategy of pursuing both psychedelic and non-hallucinogenic mechanisms across multiple underserved conditions.
AtaiBeckley Inc. was founded in 2018 and is headquartered in New York, New York. The entity is the result of a corporate restructuring, having changed its name from Atai Beckley N.V. to AtaiBeckley Inc. in December 2025.
- BPL-003 Phase 2b results in treatment-resistant depression
- FDA psychedelic therapy regulatory framework advances
- Cash runway shortens raising dilution risk
| Net Income: -663.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -2.48 > 0.02 and ΔFCF/TA -183.7 > 1.0 |
| NWC/Revenue: 6.45k% < 20% (prev 4.70k%; Δ 1.76k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -106.6m > Net Income -663.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (226.5m) vs 12m ago 28.51% < -2% |
| Gross Margin: 70.99% > 18% (prev 70.69%; Δ 0.29% > 0.5%) |
| Asset Turnover: 1.51% > 50% (prev 0.95%; Δ 0.56% > 0%) |
| Interest Coverage Ratio: -2.49k > 6 (EBIT TTM -663.1m / Interest Expense TTM 266k) |
| A: 0.85 (Total Current Assets 250.1m - Total Current Liabilities 25.0m) / Total Assets 264.9m |
| B: -5.25 (Retained Earnings -1.39b / Total Assets 264.9m) |
| C: -2.88 (EBIT TTM -663.1m / Avg Total Assets 230.3m) |
| D: 3.01 (Book Value of Equity 198.7m / Total Liabilities 66.1m) |
| Altman-Z'' = -27.72 = D |
| DSRI: 3.0 (Receivables 14.7m/1.49m, Revenue 3.49m/1.86m) |
| GMI: 1.00 (GM 70.69% / 70.99%) |
| AQI: 0.11 (AQ_t 0.04 / AQ_t-1 0.38) |
| SGI: 1.87 (Revenue 3.49m / 1.86m) |
| TATA: -2.10 (NI -663.4m - CFO -106.6m) / TA 264.9m) |
| Beneish M = -1.51 (Cap -4..+1) = CCC |
As of July 08, 2026, the stock is trading at USD 5.19 with a total of 7,694,717 shares traded. Over the past week, the price has changed by -3.17%, over one month by +36.22%, over three months by +36.94% and over the past year by +88.73%.
Current recommended Stop Loss: 4.70 (which is 9.4% or 1.3 ATR below the current price).
ATAI Life Sciences BV has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy ATAI.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14 | 169.7% |
P/S = 547.8168
P/B = 9.6173
Revenue TTM = 3.49m USD
EBIT TTM = -663.1m USD
EBITDA TTM = -662.2m USD
Long Term Debt = 1.69m USD (estimated: total debt 2.00m - short term 310k)
Short Term Debt = 310k USD (from shortTermDebt, last quarter)
Debt = 2.00m USD (from shortLongTermDebtTotal, last quarter) (leases 2.00m already included)
Net Debt = -198.7m USD (calculated: Debt 2.00m - CCE 200.7m)
Enterprise Value = 1.71b USD (1.91b + Debt 2.00m - CCE 200.7m)
Interest Coverage Ratio = -2.49k (Ebit TTM -663.1m / Interest Expense TTM 266k)
EV/FCF = -2.61x (Enterprise Value 1.71b / FCF TTM -656.8m)
FCF Yield = -38.36% (FCF TTM -656.8m / Enterprise Value 1.71b)
FCF Margin = -18.8k% (FCF TTM -656.8m / Revenue TTM 3.49m)
Net Margin = -19.0k% (Net Income TTM -663.4m / Revenue TTM 3.49m)
Gross Margin = 70.99% ((Revenue TTM 3.49m - Cost of Revenue TTM 1.01m) / Revenue TTM)
Gross Margin QoQ = 82.49% (prev none%)
Tobins Q-Ratio = 6.46 (Enterprise Value 1.71b / Total Assets 264.9m)
Interest Expense / Debt = 13.30% (Interest Expense 266k / Debt 2.00m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -523.9m (EBIT -663.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.00 (Total Current Assets 250.1m / Total Current Liabilities 35.7m)
Debt / Equity = 0.01 (Debt 2.00m / totalStockholderEquity, last quarter 198.7m)
Debt / EBITDA = 0.30 (negative EBITDA) (Net Debt -198.7m / EBITDA -662.2m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -198.7m / FCF TTM -656.8m)
Total Stockholder Equity = 181.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -288.0% (out of range, set to none)
RoE = -366.5% (Net Income TTM -663.4m / Total Stockholder Equity 181.0m)
RoCE = -363.0% (out of range, set to none) (EBIT -663.1m / Capital Employed (Equity 181.0m + L.T.Debt 1.69m))
RoIC = -218.2% (out of range, set to none) (NOPAT -523.9m / Invested Capital 240.0m)
WACC = 12.39% (E(1.91b)/V(1.91b) * Re(12.39%) + D(2.00m)/V(1.91b) * Rd(13.30%) * (1-Tc(0.21)))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 17.09%
[DCF] Fair Price = unknown (Cash Flow -656.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 89.48 | Revenue CAGR: 214.0% | SUE: 1.42 | # QB: 5
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+8.19% | Revisions=+12% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+8.73% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.44 | Chg30d=+9.32% | Revisions=+0% | GrowthEPS=+84.9% | GrowthRev=-72.9%
EPS next Year (2027-12-31): EPS=-0.46 | Chg30d=+6.28% | Revisions=-38% | GrowthEPS=-3.4% | GrowthRev=-73.0%
[Analyst] Revisions Ratio: -9% (up=9, down=11)